investorscraft@gmail.com

Stock Analysis & ValuationNervGen Pharma Corp. Common stock (NGEN)

Previous Close
$3.78
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)n/an/a
Intrinsic value (DCF)n/a
Graham-Dodd Methodn/a
Graham Formulan/a

Company Information

1455 Bellevue Avenue, Suite 301
West Vancouver, BC V7T 1C3
Canada
Phone: 604-336-8089
Industry: Biotechnology
Sector: Healthcare
CEO: Adam H. Rogers

NervGen Pharma Corp. is a clinical-stage biotechnology company developing therapies aimed at treating nerve damage and neurodegenerative conditions by targeting mechanisms that inhibit nervous system repair.

HomeMenuAccount